CS2009(PD-1/VEGF/CTLA-4三特异性抗体)的全球多中心I期研究进展顺利,截至目前在所有已评估的剂量水平中耐受性和安全性良好,并且在低剂量组的“冷肿瘤”及PD-(L)1经治患者中已观察到抗肿瘤活性,临床潜力显著。公司将在2025年欧洲内科肿瘤学会(ESMO)年会上首次揭晓CS2009的临床研究数据。CS5001(ROR1 ADC)目前临床开发进度位居全球前二,正在推进联合标准治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.